grant

Clinical feasibility study of Omega-3 PUFA therapy for the reduction of post-cardiac surgery atrial arrhythmias [ 2006 - 2008 ]

Also known as: Does omega-3 PUFA therapy reduce post-operative atrial arrhythmias?

Research Grant

[Cite as https://purl.org/au-research/grants/nhmrc/367644]

Researchers: A/Pr Salvatore Pepe (Principal investigator) ,  Prof Brian Buxton Prof Franklin Rosenfeldt Prof Julian Smith Prof Leanne Delbridge
View all 6 related researchers

Brief description The aim of this study is to determine the molecular and clinical impact of omega-3 polyunsaturated fatty acids (PUFA) pre-treatment 2 weeks before cardiac surgery in 150 patients. The outcome of this proposal will indicate proof of molecular concepts, clinical feasibility and specific design elements of a future, large scale, placebo controlled, prospective randomised trial of oral therapy with omega-3 polyunsaturated fatty acids (PUFA). Recently, omega-3 PUFA via fish diet was reported to be linked to low incidence of AF. The main aim is to provide a cheap and safe preventative therapy against post-operative atrial fibrillation (AF), a key heart rhythm disorder that occurs in at least 1 in 4 patients after heart surgery and increases post-operative complications, limits recovery and increases hospital stay and cost. Biochemical study elements are important to gain valuable insight into the molecular mechanisms (directly in human heart) that underlie post-operative heart rhythm disorder and may delineate new more precise molecular targets for therapy. No previous clinical study has ever examined whether omega-3 PUFA therapy prevents post-operative heart rhythm disorder. Use of 3g-day omega-3 PUFA pre-treatment in the surgical setting has been shown to be safe in a number of small studies, including our own. Our preliminary data indicates that therapy increases heart and blood content of omega-3 PUFA ~2-fold, and reduces the incidence of AF. Post-operative AF is an expensive resource burden in all cardiothoracic surgery units of Australian hospitals and targets key health priorities. Due to the non-patentable nature of omega-3 PUFA, significant industry based support for clinical research is limited. A positive outcome would rapidly pave the way for widespread use in elective surgery. Reduced length of hospital stay, cost-savings, and the increase in productivity as healthy individuals return to their communities would nationally repay the investment many fold.

Funding Amount $AUD 442,092.61

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Identifiers
Viewed: [[ro.stat.viewed]]